

**Ohio Department of Medicaid (ODM)
Drug Utilization Review (DUR) Board
Quarterly Meeting
September 11, 2018**

The ODM DUR Board meeting was called to order at 12:00 PM EST in room C621 A&B, 50 West Town Street, Columbus, Ohio. Donald Sullivan, R.Ph. presided

The following Board members were present:

David Brookover, R.Ph.

Michael Dietz, DO.

Michael Farrell, MD.

Robert Kubasak, R.Ph.

Mehran Mostafavifar, MD., Co-Chair.

Leonard Presutti, DO.

Donald Sullivan, R.Ph., Chair.

Also present from ODM were Tracey Archibald, Pharm. D., DUR Administrator, and Michelle Barger, Pharm.D. Change Healthcare attendees included Benjamin Link, Pharm.D. and Gail Master, R.Ph. Approximately 18 observers were present, mostly representing pharmaceutical manufacturers.

Roll Call, Reading, Correction, and Approval of Previous Minutes

The May 8, 2018 DUR Board Meeting minutes were approved.

DUR Committee Report

G. Master presented a summary on a retrospective drug utilization review (RetroDUR) intervention focusing on levetiracetam doses greater than 3,000mg/day. Discussion ensued regarding whether the prescribing neurologist should be contacted as a potential next step. The Board decided that if the patient is seeing the neurologist annually, this was not necessary, and no hard edits should be placed on this dose in pharmacy claims.

G. Master presented the opioid high dose MED>400 intervention. Discussions involved the patient's functionality status and pain control. A question was raised about the geography of the patients and access to a pain specialist. The Board also pointed out that there have been no interventions or guidelines around semi acute pain and recommended a future RetroDUR intervention on this topic. G. Master reviewed the Coordinated Services Program (CSP) and results for the program thus far.

Health Plan Policy

T. Archibald announced that the annual PDL review P&T Meeting will be held on October 3, 2018. The agenda and draft PDL have been posted to the website. Classes will be extracted as usual. The single PDL classes to be extracted include: Diabetes: Insulin, Diabetes: Non-Insulin, Hepatitis C and Medication Assisted Treatment (MAT) for Opioid Use Disorder.

T. Archibald also announced that Myers and Stauffer are the selected vendor for the 2018 cost of dispensing survey. Surveys are to be mailed to pharmacies on 9/12/18. Six DUR Committee members are in the process to be onboarded for the October DUR committee meeting and 1 member is in process for the DUR Board.

D. Sullivan asked about the plans to require the Managed Care Plans (MCPs) in Ohio to move towards a pass-through billing arrangement. T. Archibald commented that the department is moving forward with this 1/1/2019.

Unfinished Business

There was no unfinished business.

New Business

G. Master discussed a RetroDUR intervention that targets prescribers who have patients taking a muscle relaxant for greater than 90 days. 369 members were identified for this intervention. A question was raised whether Ohio Medicaid covers osteopathic manipulation and massage therapy. Discussion ensued regarding whether additional educational documentation can be included in the letters.

G. Master also presented a RetroDUR intervention which focuses on the chronic use of albuterol without a controller medication. It was suggested to add to the letter a confirmation of the diagnosis by a pulmonary function test.

B. Link presented the proposed criteria for prior authorization on compounds. Discussions revolved around the \$100 limit, the ingredients of the compound, and whether a certain specialist will be additionally burdened by the prior authorization process.

The Board requested more information about the most common compound claims that would require prior authorization for exceeding the \$100 limit to be provided to decide on the requirements.

Announcements

The date for the next DUR Board meetings is November 13th at 12 pm at ODM room c621.

Adjournment

Donald Sullivan, R.Ph. adjourned the meeting at 1:13 P.M